DAC
BMY.RT

Dividend Assets Capital’s Bristol-Myers Squibb Company Contingent Value Rights BMY.RT Stock Holding History

Dividend Assets Capital’s Portfolio BMY.RT Stock Details BMY.RT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-484
Closed – – 570
2020
Q4 		$0 Hold
484
– – ﹤0.01% 574
2020
Q3 		$1K Hold
484
– – ﹤0.01% 189
2020
Q2 		$2K Hold
484
– – ﹤0.01% 183
2020
Q1 		$2K Buy
484
+201
+71% +$662 ﹤0.01% 172
2019
Q4 		$1K Buy
+283
New +$736 ﹤0.01% 192

Other funds holding BMY.RT

JCI
Jet Capital Investors New York $51M AUM 48.01% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return
BC
Brookfield Corp Toronto, Ontario, Canada $74.2B AUM 0.68% 1-Year Est. Return
TNB
Thomasville National Bank Thomasville, Georgia $1.82B AUM
WAM
Westport Asset Management Southport, Connecticut $226M AUM 16.76% 1-Year Est. Return
IAIM
International Assets Investment Management Orlando, Florida $1.67B AUM 28.26% 1-Year Est. Return

Dividend Assets Capital's BMY.RT Position: Q1 2021 in Review

Dividend Assets Capital sold out of Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) in Q1 2021, closing a stake of 484 shares.

Dividend Assets Capital first reported a position in BMY.RT in Q4 2019 and held it in 5 quarters. The position peaked at $2K in Q2 2020. 12 funds tracked by Wall St. Rank hold BMY.RT as of Q1 2021.

  • Dividend Assets Capital reported no remaining Bristol-Myers Squibb Company Contingent Value Rights position as of Q1 2021 after selling out during the quarter.
  • Dividend Assets Capital sold 484 Bristol-Myers Squibb Company Contingent Value Rights shares in Q1 2021.
  • Dividend Assets Capital first reported a position in Bristol-Myers Squibb Company Contingent Value Rights in Q4 2019 and held it in 5 quarters.
  • Dividend Assets Capital's Bristol-Myers Squibb Company Contingent Value Rights position peaked at $2K in Q2 2020.
  • 12 funds tracked by Wall St. Rank held Bristol-Myers Squibb Company Contingent Value Rights as of Q1 2021.

Based on Dividend Assets Capital's 13F filing for Q1 2021, filed 28 Apr 2021.